Table 2.
Donor | Passage |
Norm. karyotype (%) |
Clonal aneupl. (%) |
Clonal struct. abnorm (%) |
Random loss (%) | Random gain (%) | Metaphases (number) | Metaphases/Cells (number) | Mitotic index (%) |
1 (46,XX) |
7 | 45.5 | 0 | 0 | 54.5 | 0 | 22 | 24/1038 | 2.3 |
9 | 66.7 | 0 | 0 | 33 | 0 | 39 | 8/1000 | 0.8 | |
12a | 60 | 0 | 0 | 40 | 0 | 5 | 15/1000 | 1.5 | |
2 (46,XY) |
6 | 82.8 | 0 | 0 | 15.6 | 1.6 | 64 | 70/1000 | 7.0 |
10 | 80 | 0 | 0 | 20 | 0 | 30 | 24/1010 | 2.4 | |
16a | 45.5 | 0 | 0 | 36.4 | 18.1 | 11 | 11/1007 | 1.1 | |
3 (46,XX) |
3 | 70 | 0 | 0 | 26 | 4 | 23 | 4/1032 | 0.4 |
4 (46,XX) |
3 | 78 | 0 | 0 | 22 | 0 | 27 | 16/1000 | 1.6 |
6 | 70.4 | 0 | 0 | 25.9 | 3.7 | 27 | 16/1000 | 1.6 | |
9 | 41.2 | 52.9 (47,XX,+7) | 0 | 5.9 | 0 | 17 | 2/1320 | 0.2 | |
12 | 30.6 | 50 (47,XX,+7) and 11.1 (46,X,+7) | 0 | 8.3 | 0 | 36 | 16/1000 | 1.6 | |
5 (46,XX) |
4 | 33.3 | 33.3 (49,XX,+5,+7,+9) | 0 | 33.3 | 0 | 18 | 12/1011 | 1.2 |
6 | 80 | 0 | 0 | 12 | 8 | 25 | 7/1000 | 0.7 | |
10 | 81.3 | 0 | 0 | 18.7 | 0 | 32 | 14/1080 | 1.3 | |
12 | 92.3 | 0 | 0 | 7.7 | 0 | 26 | 18/1028 | 1.8 | |
6 (46,XY) |
4 | 86 | 0 | 0 | 14 | 0 | 50 | 47/1000 | 4.7 |
6 | 76.5 | 0 | 0 | 23.5 | 0 | 17 | 2/1001 | 0.2 | |
9 | 82.7 | 0 | 0 | 17.3 | 0 | 53 | 41/1000 | 4.1 | |
12a | 72.7 | 0 | 0 | 18.2 | 9.1 | 11 | 1/1000 | 0.1 | |
7 (46,XX) |
4 | 90.6 | 0 | 0 | 3.1 | 6.3 | 32 | 49/1011 | 4.8 |
6 | 92.9 | 0 | 0 | 7.1 | 0 | 14 | 2/1000 | 0.2 | |
9 | 81.3 | 0 | 0 | 18.7 | 0 | 16 | 11/1029 | 1.1 | |
8 (46,XY) |
4 | 100 | 0 | 0 | 0 | 0 | 37 | 27/1030 | 2.6 |
6 | 78.1 | 0 | 0 | 17 | 4.9 | 41 | 22/1088 | 2.0 | |
9 | 77 | 0 | 0 | 23 | 0 | 30 | 6/1000 | 0.6 |
aIn senescence. Clonal aneupl., clonal aneuploidies; Struct. abnorm., structural abnormalities.